LUTRIS PHARMA LTD has a total of 20 patent applications. It increased the IP activity by 50.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, measurement and organic fine chemistry are HARBIN ZHENBAO PHARMACEUTICAL CO LTD, HANGZHOU ZHUYANGXIN PHARMACEUTICAL CO LTD and SHANGHAI SINE PROMOD PHARMACEUTICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Republic of Korea | 2 | |
#7 | Australia | 1 | |
#8 | Brazil | 1 | |
#9 | Israel | 1 | |
#10 | Japan | 1 | |
#11 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Analysing materials | |
#4 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Shelach Noa | 18 |
#2 | Noa Shelach | 2 |
#3 | Lowenton-Spier Noa | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020165755A1 | Use of topical braf inhibitor compositions for treatment of radiation dermatitis | |
BR112020001935A2 | new braf inhibitors and their use for the treatment of skin reactions | |
EP3426254A1 | Use of braf inhibitors for treating cutaneous reactions |